ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$4.15▲ +4.01%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Corbus Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Corbus Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Corbus Pharmaceuticals a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $3.59 and $4.64; in 9 out of 10, between $2.86 and $5.82. Estimated annual volatility is 71%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- $18.11
- 52-week low
- $3.87
- Revenue (12 months)
- $0.0M
- Return on equity
- -95.6%
- Free cash flow (12 months)
- $-49.6M
- Beta
- 2.64
What this means
ATLAS does not publish a fair value for CRBP right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CRBP has traded between $3.87 and $18.11. Today it is 77.1% below that high and 7% above its low.
Its beta is 2.64: it tends to move more than the market, both up and down.
About the company
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.
Want to see everything about Corbus Pharmaceuticals?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does Corbus Pharmaceuticals do?
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.
What is the chance CRBP goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, CRBP ends the month between $3.59 and $4.64.
How volatile is CRBP?
ATLAS estimates annual volatility at 71%. In a typical month, half of the outcomes end between $3.59 and $4.64.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer